✦ LIBER ✦

Therapeutic options for Bowen’s disease

✍ Scribed by Gilberto Moreno; Alvin LK Chia; Adrian Lim; Stephen Shumack

Book ID: 108928650
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 90 KB
Volume: 48
Category: Article
ISSN: 0004-8380
DOI: 10.1111/j.1440-0960.2007.00317.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bowen’s disease: where now with therapeu

Bowen’s disease: where now with therapeutic trials?

✍ N.H. Cox 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB

Methyl aminolaevulinate photodynamic the

Methyl aminolaevulinate photodynamic therapy for Bowen's disease: A practical option?

✍ Colin A. Morton 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 30 KB

Methyl aminolaevulinate photodynamic the

Methyl aminolaevulinate photodynamic therapy for Bowen's disease: A practical option?

✍ Colin A. Morton 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 30 KB

BOWEN'S DISEASE

✍ V. J. McGovern 📂 Article 📅 1965 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

Therapeutic options for premature corona

Therapeutic options for premature coronary artery disease

✍ Ameen F. Person; Cam Patterson 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 255 KB

New insights into therapeutic options fo

New insights into therapeutic options for Pompe disease

✍ Emmanuel Richard; Gaëlle Douillard-Guilloux; Catherine Caillaud 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

## Abstract Glycogen storage disease type II or Pompe disease (GSD II, MIM 232300) is a rare inherited metabolic myopathy caused by a deficiency of lysosomal acid α‐glucosidase or acid maltase (GAA; EC 3.2.1.20), resulting in a massive lysosomal glycogen accumulation in cardiac and skeletal muscles